In December 2017 the Canadian Leadership Council on Drug Plan Partnerships met to discuss how Private and Pharmacare can partner to share in the risks of a National Drug Program. Included in this meeting were our own Paul Crossdale, President MC&A and Kathleen...
A group benefits plan, and/or retirement savings plan, can be integrated with benefits paid by either your Provincial or the Federal arm of government. It is important to understand what these government benefits are and how they impact your employee benefits plan...
Statement by Minister of Health and Long-Term Care January 29, 2018 The following statement was issued today by Dr. Eric Hoskins, Minister of Health and Long-Term Care, following an announcement by the pan-Canadian Pharmaceutical Alliance and the Canadian Generic...
Summary of Bill 148- Changes to Employment Standards Act, 2000 Attached is a summary of changes for the upcoming year impacting the Employment Standard Act, 2000. Many of the proposed changes to the Employment Standards Act are scheduled to take place on a rolling...
Canada’s first major biosimilar drug appears to be having a rough start in the private group insurance industry. Meanwhile, it looks like much smoother sailing for public drug plans, which are going ahead with preferred listing status for Inflectra based on a price...
A Quebec employer recently boasted about its unconventional hiring policy – the company has never hired a “smoker” in its 30 years as a business, and its proud of this stance. News like this is mildly shocking in Canada, where the idea of health outcomes, personal...
